PATENT CLAIM ANALYSIS

Application Number: 16099673
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-05
Patent Classification: ["514", "211130"]

Abstract:
Alcoholism, and symptoms and negative effects thereof may be treated using ibudilast or a pharmaceutically acceptable salt thereof. Patients diagnosed with alcohol use disorder and who exhibit symptoms of depression and/or dysphoric mood can be treated using ibudilast or a pharmaceutically acceptable salt thereof.

Claim (Index 18):
The method of  claim 17 , wherein the psychiatric therapeutic agent is lithium, sertraline, citalopram, carbamazepine, amisulpride, clomipramine, gabapentin, amitriptyline, doxepin, lamotrigine, amoxapine, escitalopram, levetiracetam, agomelatin, fluoxetine, bupropion, fluvoxamine, oxcarbazepine, imipramine, topiramate, clomipramine, mirtazapine, sodium valproate, desipramine, paroxctine, divalproex sodium, desvenlafaxine, sodium valproate, duloxetine, escitalopram, moclobemide, nortripytline, phenelzine, reboxetine, tianeptine, tranylcypromine, trazodone, venlafaxine, vilazodone, vortioxetine, or any combination of one or more of the foregoing.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 98.0
- Lexical Diversity: 1.46875
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15851066', '14188061', '15527280', '11527757', '11295730']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7797332368333973
- 35 USC 102 Novelty (BERT): 0.5164105413282667
- Combined Prediction Score: 0.7534009672828843
- Mean Citation Score: 247.868772
- Max Citation Score: 307.0052
- Similarity Product: 233.5525759771824

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test